INHBE (siRNA)
VIAL-INHBE is designed to block Activin E signaling and increase lipolysis for fat-selective weight loss, which could maintain high quality weight loss during and post-GLP-1 cessation.
- Pre-clinical studies demonstrate fat-selective weight loss and off-treatment weight maintenance.
- Additional key IND-enabling study readouts in Q4 2025.
- Phase 1 FPI in Q1 2026.
Key Data
Based on in vitro and in vivo studies, VIAL-INHBE effectively demonstrates functional potency and target-binding comparable to or better than clinical programs.
In DIO mice
- VIAL-INHBE treatment leads to fat-selective weight loss and weight loss is maintained post-treatment cessation.
- VIAL-INHBE supports fat loss maintenance post-GLP-1 treatment cessation.
- VIAL-INHBE is synergistic with GLP-1 treatment to support added fat loss and weight loss.
Lead series data
- Lead series shows high stability in NHP liver lysates (S9 fractions) during the 72 hr incubation, indicating potential for a favorable dosing interval.
- Lead series displays robust knockdown potency in primary human hepatocytes, indicating potential for strong efficacy.
- Lead series displays low risk of immunogenicity in human PBMCs, indicating potential for a strong safety profile.
